MANITEX CAPITAL INC. ("MNX")
BULLETIN TYPE: Property-Asset or Share Disposition Agreement
BULLETIN DATE: October 3, 2014
TSX Venture Tier 2 Company
TSX Venture Exchange has accepted for filing documentation pertaining to an Asset Purchase Agreement (the "Agreement"), dated July 11, 2014, between Valeo Pharma Inc. - a 40% owned subsidiary of Manitex Capital Inc. (the "Vendor") and Valeant Canada LP (the "Purchaser"), whereby the Vendor has completed the sale of its dermatology portfolio and several specialty products for aggregate consideration of $25.3 million, of which $18.3 million will be paid in cash on closing with the balance subject to certain post-closing adjustments to take place over a three year period.
For further information, please refer to the Company's news release dated August 25, 2014.
________________________________________
|
|
